Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting
February 10, 2022 17:33 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on February 24, 2022 at 8:00 a.m. Eastern Time
February 10, 2022 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on...
Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer
January 27, 2022 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a...
Lantheus Appoints Vivian Yao as Chief Human Resources Officer
December 01, 2021 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces PYLARIFY AI™ is Now Available
November 29, 2021 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022
November 22, 2021 08:30 ET
|
Lantheus Holdings, Inc.
PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings,...
Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings
November 17, 2021 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 16, 2021 16:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results
November 04, 2021 07:00 ET
|
Lantheus Holdings, Inc.
Worldwide revenue of $102.1 million for the third quarter 2021, representing an increase of 15.3% from the prior year periodGAAP net loss of $13.4 million for the third quarter 2021, compared to GAAP...
Lantheus Holdings to Present at Upcoming Investor Conferences
October 28, 2021 16:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging...